World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
46215
World Ranking
6983
National Ranking
3673

Vernon K. Sondak publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Vernon K. Sondak sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 618 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Vernon K. Sondak D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Vernon K. Sondak sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Vernon K. Sondak is affiliated with the University of South Florida in the United States. Their research primarily focuses on medicine, with a strong emphasis on oncology. Within oncology, their work further explores molecular biology, immunology, and epidemiology, with additional contributions related to electrical and electronic engineering.

The scientist's main research topics include:

  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Polyomavirus and related diseases
  • Nonmelanoma Skin Cancer Studies

Vernon K. Sondak has contributed multiple papers in high-profile medical and oncology journals. Some of their recent papers are:

  • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma, 2023, New England Journal of Medicine
  • Systemic Therapy for Melanoma: ASCO Guideline, 2020, Journal of Clinical Oncology
  • ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee, 2020, Annals of Oncology
  • Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma, 2021, Journal of Clinical Oncology
  • Systemic Therapy for Melanoma: ASCO Guideline Update, 2023, Journal of Clinical Oncology

Frequent coauthors who have collaborated extensively with Vernon K. Sondak include:

  • Ahmad A. Tarhini (41 joint publications)
  • Jonathan S. Zager (40 joint publications)
  • John M. Kirkwood (30 joint publications)
  • Nikhil I. Khushalani (30 joint publications)
  • Jane L. Messina (29 joint publications)

The scientist's work appears regularly in several publication venues, prominently:

  • Journal of Clinical Oncology (23 publications)
  • Annals of Surgical Oncology (17 publications)
  • Annals of Oncology (12 publications)
  • Journal for ImmunoTherapy of Cancer (9 publications)
  • Regular and Young Investigator Award Abstracts (9 publications)

Vernon K. Sondak's research career spans multiple domains within medicine and oncology, with a particular focus on melanoma and immunotherapy. Their interdisciplinary approach integrates molecular biology, immunology, and clinical oncology to advance understanding and management of skin cancers and associated immune responses.

Best Publications

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Molecular classification of cutaneous malignant melanoma by gene expression profiling

    M. Bittner;P.S.J. Meltzer;Y.D. Chen;Y. Jiang

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

    John M. Kirkwood;Joseph G. Ibrahim;Jeffrey A. Sosman;Vernon K. Sondak

  • High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

    John M. Kirkwood;Joseph G. Ibrahim;Vernon K. Sondak;Jon Richards

  • Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

    Adil I. Daud;Ronald C. DeConti;Stephanie Andrews;Patricia Urbas

  • Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

    Edward L. Korn;Ping Yu Liu;Sandra J. Lee;Judith Anne W. Chapman

  • Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system

    Bianca D. Lemos;Barry E. Storer;Jayasri G. Iyer;Jerri Linn Phillips

  • A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

    John M. Kirkwood;Judith Manola;Joseph Ibrahim;Vernon Sondak

  • PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

    Kim H.T. Paraiso;Yun Xiang;Vito W. Rebecca;Ethan V. Abel

  • Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.

    P Piedbois;M Buyse;N Kemeny

  • Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

    Jane L. Messina;David A. Fenstermacher;Steven Eschrich;Xiaotao Qu

  • Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database

    John F. Thompson;Seng Jaw Soong;Charles M. Balch;Jeffrey E. Gershenwald

  • Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study

    George J. Brewer;Robert D. Dick;Damanjit K. Grover;Virginia LeClaire

  • Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

    Michael B. Atkins;Jessie Hsu;Sandra Lee;Gary I. Cohen

  • Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

    K H T Paraiso;I V Fedorenko;L P Cantini;A C Munko

  • Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model.

    Vernon K. Sondak;Jeremy M. G. Taylor;Michael S. Sabel;Yue Wang

  • Molecular classification of cutaneous malignant melanoma by gene expression profiling

    M. Bittner;P. Meltzer;Y. Chen;Y. Jiang

  • Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

    Kim H. Paraiso;Vito Rebecca;Inna V. Fedorenko;Yun Xiang

Frequent Co-Authors

Jane L. Messina
Jane L. Messina University of South Florida
John M. Kirkwood
John M. Kirkwood University of Pittsburgh
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Jeffrey E. Gershenwald
Jeffrey E. Gershenwald The University of Texas MD Anderson Cancer Center
Alfred E. Chang
Alfred E. Chang University of Michigan–Ann Arbor
John F. Thompson
John F. Thompson University of Sydney
Timothy M. Johnson
Timothy M. Johnson University of Michigan–Ann Arbor
Jeffrey S. Weber
Jeffrey S. Weber New York University
Adil Daud
Adil Daud University of California, San Francisco
Antoni Ribas
Antoni Ribas University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medical careers with flexible learning options? Online pathways now make it easier than ever to advance in healthcare without putting your life on hold. For current RNs, rn to bsn programs without clinicals provide a convenient route to a bachelor’s degree, often allowing students to bypass traditional on-site practicums.

Those seeking the highest level of clinical nursing practice can consider dnp programs online, which are available in accelerated and flexible formats for experienced nurses. Some online dnp programs without clinicals further lower barriers, accommodating professionals who want to advance without extensive in-person requirements.

If you’re starting your career, lpn online programs offer a fast-track entry into the workforce and can serve as stepping stones to higher qualifications. These innovative online options can help you tailor your educational journey, save time, and open doors to rewarding roles in the healthcare sector.

Best Scientists Citing Vernon K. Sondak

Trending Scientists

Recently Published Articles